DarioHealth Corp logo

DarioHealth Corp(DRIO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.32
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for DRIO

11/20/2026: DRIO (1-star) is currently NOT-A-BUY. Pass it for now.

DarioHealth Corp is a digital health company that provides a multi-condition platform for managing chronic illnesses like diabetes and hypertension. The company's primary strength lies in its expanding B2B2C enterprise distribution model and integrated software-plus-device ecosystem. Its main growth opportunity centers on scaling enterprise health plan contracts and cross-selling newly acquired behavioral and respiratory health solutions. However, key risks include intense competition, ongoing operating losses, and cash burn management. The stock suits growth-oriented investors willing to accept high volatility while monitoring enterprise customer adoption and cash runway milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers exposure to expanding digital health trends, though consistent profitability is still under development.
Momentum investorStrong fit while signal remains positiveStock can experience sharp upward moves on commercial partnership announcements or earnings surprises.
Value investorWeak fitThe company lacks current earnings and positive free cash flow, making traditional value metrics unappealing.
Dividend investorWeak fitDarioHealth pays no dividends as it prioritizes growth and commercial scaling.
Low-risk investorWeak fitHigh share price volatility and small-cap risk profile present substantial downside exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap digital health stocks frequently experience sharp price swings based on macro sentiment and quarterly updates.
Valuation riskMedium / highValuations can compress rapidly if top-line growth metrics fail to meet market expectations.
Competition risk (Digital health & remote monitoring platforms)HighCompetition from well-capitalized remote care and telehealth providers threatens customer acquisition rates.
Business qualityMediumThe software-plus-device model has long-term merit, but commercial scaling is still maturing.
Dividend incomeLow / noneNo dividend is offered, providing zero income return for investors.
Execution riskHighSuccessfully integrating multiple acquisitions and scaling enterprise health plan contracts requires flawless execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.90M USD
Price to earnings Ratio -
1Y Target Price 8
Price to earnings Ratio -
1Y Target Price 8
Volume (30-day avg) 74.7K shares
Beta 1.18
52 Weeks Range 1.09 - 14.49
Updated Date 11/21/2026
52 Weeks Range 1.09 - 14.49
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.53

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
2 / 2
30-Day BUY Count Change
0

Eligible universe: 2 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -65.72%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
DRIO receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
DRIO has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+2.4%) is partially offset by weak cash generation (FCF margin -116.7%), negative revenue growth (-17.3%), weak profitability (net margin -186.6%).

Financial Health Rating

★★★★★
DRIO's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 23.4%). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is DRIO's strongest growth driver at +32.6% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (-17.3%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 15.4% and approximately 66.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 18.80% supports management-shareholder alignment.

Top 5 Institutional Investors

Nantahala Capital Management, LLC 12.47%
Vanguard Capital Management, LLC 0.67%
Geode Capital Management, LLC 0.59%
BlackRock Inc 0.39%
Vanguard Fiduciary Trust Co 0.38%

Unit Economics (Per $1K Revenue)

★★★★★
DRIO generates approximately $566 of gross profit, $-1,639 of operating income, and $-1,167 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.25% (Tax Credit)

Quantitative Style Profile

★★★★★
DRIO has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
B2B2C Enterprise SolutionsSoftware subscriptions, platform licensing, and coaching services sold to health plans, self-insured employers, and health systems.This is the primary growth engine where DarioHealth scales recurring revenues through corporate and insurance channels.
Consumer DirectDirect sale of blood glucose meters, testing supplies, and recurring consumer app subscriptions via retail channels and e-commerce.Provides a direct baseline revenue stream from individual users managing their chronic conditions independently.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 10.59
Enterprise Value 16.32M
Price to Sales(TTM) 0.7
Enterprise Value 16.32M
Price to Sales(TTM) 0.7
Enterprise Value to Revenue 0.77
Enterprise Value to EBITDA -0.59
Shares Outstanding 11.29M
Shares Floating 7.53M
Shares Outstanding 11.29M
Shares Floating 7.53M
Percent Insiders 18.8
Percent Institutions 15.37

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.